<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00130286</url>
  </required_header>
  <id_info>
    <org_study_id>65515</org_study_id>
    <secondary_id>R01DK065515</secondary_id>
    <nct_id>NCT00130286</nct_id>
  </id_info>
  <brief_title>Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Recombinant Human Growth Hormone and/or Rosiglitazone in the Treatment of Human Immunodeficiency Virus-Associated Visceral Adiposity and Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if the combination of recombinant human growth
      hormone plus rosiglitazone (an insulin-sensitizing drug) is safe and more effective than
      either drug alone (or no active therapy) for the treatment of fat accumulation in people with
      HIV infection and insulin resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A number of people with HIV infection who gain weight in the abdomen (sometimes called
      lipodystrophy) also have a high level of the sugar-controlling hormone called insulin. These
      people need to produce this extra insulin to help keep their blood sugar normal. This is
      called &quot;insulin resistance.&quot;

      Studies have shown that growth hormone (also called &quot;Serostim&quot;) can decrease abdominal fat,
      but it can also worsen the insulin resistance. Rosiglitazone (also called &quot;Avandia&quot;) is used
      to treat insulin resistance in people who have diabetes, so we want to see if taking growth
      hormone and rosiglitazone together will be better for treating the fat accumulation part of
      lipodystrophy than either drug alone or no active therapy.

      The study is 24 weeks long, divided into two 12-week parts.

      The first part of the study is double-blind, meaning that neither participants nor the study
      staff will know which drugs participants are on. Participants will be assigned randomly (like
      flipping a coin) to one of four groups:

        1. Growth hormone (one injection, daily) PLUS rosiglitazone (one tablet, twice daily).

        2. Growth hormone PLUS rosiglitazone placebo (&quot;sugar pill&quot;).

        3. Growth hormone placebo (plain water injection) PLUS rosiglitazone.

        4. Growth hormone placebo PLUS rosiglitazone placebo.

      Everyone in the study will need to be hospitalized overnight for special tests at the
      beginning of the study and at week 12.

      The second part of the study is open-label, meaning that participants and the study staff
      will know which drugs participants are receiving. All volunteers will receive both active
      drugs:

        -  Growth hormone (one 2 mg injection, every other day) PLUS rosiglitazone (one 4 mg
           tablet, twice daily).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Insulin Sensitivity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in insulin sensitivity value from baseline to week 12 by frequently sampled intravenous glucose tolerance test
This assessment was only conducted at baseline and week 12; therefore the change reflects the difference between these two time points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Visceral Adipose Tissue Volume</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in visceral adipose tissue volume from baseline to week 12 measured by whole body MRI
Data are presented only for subjects who had MRI scans done at both time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Subcutaneous Adipose Tissue Volume</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in subcutaneous adipose tissue volume from baseline to week 12 by whole body MRI
Data are presented only for subjects who had MRI scans done at both time points.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>HIV-Associated Lipodystrophy Syndrome</condition>
  <condition>Insulin Resistance</condition>
  <condition>HIV Infections</condition>
  <condition>Metabolic Syndrome X</condition>
  <condition>Body Weight Changes</condition>
  <arm_group>
    <arm_group_label>rhGH + rosi</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant human growth hormone + rosiglitazone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhGH placebo + rosi</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo for recombinant human growth hormone + rosiglitazone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhGH + rosi placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant human growth hormone + placebo for rosiglitazone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for recombinant human growth hormone + placebo for rosiglitazone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosiglitazone</intervention_name>
    <description>4 mg tablet twice a day x 12 weeks (double-blind phase)</description>
    <arm_group_label>rhGH + rosi</arm_group_label>
    <arm_group_label>rhGH placebo + rosi</arm_group_label>
    <arm_group_label>rhGH + rosi placebo</arm_group_label>
    <arm_group_label>Double placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human growth hormone + rosiglitazone</intervention_name>
    <description>Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)</description>
    <arm_group_label>rhGH + rosi</arm_group_label>
    <arm_group_label>rhGH placebo + rosi</arm_group_label>
    <arm_group_label>rhGH + rosi placebo</arm_group_label>
    <arm_group_label>Double placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-infected

          -  On stable Food and Drug Administration (FDA)-approved antiretrovirals for at least 8
             weeks

          -  Excess abdominal fat based on waist and hip measurements done at the screening visit.
             [waist greater than 34.7 inches (men) or 29.6 inches (women) and waist to hip ratio
             greater than 0.95 (men) or 0.9 (women)]

          -  Evidence of insulin resistance (based on fasting glucose and insulin levels done at
             screening)

          -  Triglycerides less than 750 mg/dL

        Exclusion Criteria:

          -  Pregnancy

          -  Active AIDS-defining infection or other acute illness, within 30 days of entry.

          -  Active cancer (except for localized Kaposi's sarcoma) or active brain tumor

          -  Any diagnosis of pancreatitis, carpal tunnel syndrome, diabetes, angina, coronary
             artery disease, or disorder associated with fluid retention (examples: cirrhosis,
             congestive heart failure)

          -  Untreated or uncontrolled high blood pressure, within 30 days of entry.

          -  Within 12 weeks of study entry, use of the following:

               -  Obesity (fat-reducing) drugs.

               -  Anti-diabetic or insulin-sensitizing drugs (examples: rosiglitazone,
                  pioglitazone, or metformin).

               -  Systemic glucocorticoids (example: prednisone).

               -  Growth hormone or any medication for AIDS-associated wasting.

               -  Systemic chemotherapy, interferon, or radiation therapy.

               -  Androgenic agents [examples: nandrolone, oxandrolone (Oxandrin) (testosterone
                  replacement therapy is permitted if started more than 30 days before entry)]

               -  Appetite stimulants (Marinol, Megace, Periactin).

          -  Use of cholesterol lowering drugs, unless started more than 12 weeks before entry

          -  Inability to have a magnetic resonance imaging (MRI) scan performed (examples: cardiac
             pacemaker, intracranial aneurysm clips)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marshall J Glesby, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AIDS Community Research Initiative of America (ACRIA)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell HIV Clinical Trials Unit, Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's-Roosevelt Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University College of Physicians and Surgeons</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Glesby MJ, Albu J, Chiu YL, Ham K, Engelson E, He Q, Muthukrishnan V, Ginsberg HN, Donovan D, Ernst J, Lesser M, Kotler DP. Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial. PLoS One. 2013 Apr 12;8(4):e61160. doi: 10.1371/journal.pone.0061160. Print 2013.</citation>
    <PMID>23593417</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2005</study_first_submitted>
  <study_first_submitted_qc>August 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2005</study_first_posted>
  <results_first_submitted>December 16, 2013</results_first_submitted>
  <results_first_submitted_qc>February 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 13, 2014</results_first_posted>
  <last_update_submitted>February 10, 2014</last_update_submitted>
  <last_update_submitted_qc>February 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Weill Medical College of Cornell University</investigator_affiliation>
    <investigator_full_name>Marshall Jay Glesby, MD, PhD</investigator_full_name>
    <investigator_title>Professor of Medicine and Public Health</investigator_title>
  </responsible_party>
  <keyword>Lipodystrophy</keyword>
  <keyword>HIV</keyword>
  <keyword>Growth hormone</keyword>
  <keyword>Rosiglitazone</keyword>
  <keyword>Visceral fat</keyword>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Treatment Experienced</keyword>
  <keyword>Visceral fat accumulation</keyword>
  <keyword>fat accumulation</keyword>
  <keyword>HIV-Associated Metabolic Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Lipodystrophy</mesh_term>
    <mesh_term>Body Weight Changes</mesh_term>
    <mesh_term>HIV-Associated Lipodystrophy Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>rhGH + Rosi</title>
          <description>Recombinant human growth hormone + rosiglitazone
Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)
Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)</description>
        </group>
        <group group_id="P2">
          <title>rhGH Placebo + Rosi</title>
          <description>Placebo for recombinant human growth hormone + rosiglitazone
Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)
Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)</description>
        </group>
        <group group_id="P3">
          <title>rhGH + Rosi Placebo</title>
          <description>Recombinant human growth hormone + placebo for rosiglitazone
Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)
Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)</description>
        </group>
        <group group_id="P4">
          <title>Double Placebo</title>
          <description>Placebo for recombinant human growth hormone + placebo for rosiglitazone
Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)
Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing lab specimens</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>rhGH + Rosi</title>
          <description>Recombinant human growth hormone + rosiglitazone
Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)
Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)</description>
        </group>
        <group group_id="B2">
          <title>rhGH Placebo + Rosi</title>
          <description>Placebo for recombinant human growth hormone + rosiglitazone
Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)
Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)</description>
        </group>
        <group group_id="B3">
          <title>rhGH + Rosi Placebo</title>
          <description>Recombinant human growth hormone + placebo for rosiglitazone
Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)
Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)</description>
        </group>
        <group group_id="B4">
          <title>Double Placebo</title>
          <description>Placebo for recombinant human growth hormone + placebo for rosiglitazone
Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)
Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="17"/>
            <count group_id="B4" value="19"/>
            <count group_id="B5" value="77"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.8" spread="9.4"/>
                    <measurement group_id="B2" value="49.3" spread="6.1"/>
                    <measurement group_id="B3" value="48.6" spread="4.9"/>
                    <measurement group_id="B4" value="46.6" spread="6.7"/>
                    <measurement group_id="B5" value="47.9" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Insulin Sensitivity</title>
        <description>Change in insulin sensitivity value from baseline to week 12 by frequently sampled intravenous glucose tolerance test
This assessment was only conducted at baseline and week 12; therefore the change reflects the difference between these two time points.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rhGH + Rosi</title>
            <description>Recombinant human growth hormone + rosiglitazone
Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)
Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)</description>
          </group>
          <group group_id="O2">
            <title>rhGH Placebo + Rosi</title>
            <description>Placebo for recombinant human growth hormone + rosiglitazone
Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)
Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)</description>
          </group>
          <group group_id="O3">
            <title>rhGH + Rosi Placebo</title>
            <description>Recombinant human growth hormone + placebo for rosiglitazone
Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)
Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)</description>
          </group>
          <group group_id="O4">
            <title>Double Placebo</title>
            <description>Placebo for recombinant human growth hormone + placebo for rosiglitazone
Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)
Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Sensitivity</title>
          <description>Change in insulin sensitivity value from baseline to week 12 by frequently sampled intravenous glucose tolerance test
This assessment was only conducted at baseline and week 12; therefore the change reflects the difference between these two time points.</description>
          <units>uU*10^-4*min*ml^-1</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" lower_limit="-0.37" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.44" lower_limit="0.68" upper_limit="2.59"/>
                    <measurement group_id="O3" value="-0.63" lower_limit="-1.03" upper_limit="0.11"/>
                    <measurement group_id="O4" value="0.14" lower_limit="-0.41" upper_limit="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Visceral Adipose Tissue Volume</title>
        <description>Change in visceral adipose tissue volume from baseline to week 12 measured by whole body MRI
Data are presented only for subjects who had MRI scans done at both time points.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rhGH + Rosi</title>
            <description>Recombinant human growth hormone + rosiglitazone
Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)
Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)</description>
          </group>
          <group group_id="O2">
            <title>rhGH Placebo + Rosi</title>
            <description>Placebo for recombinant human growth hormone + rosiglitazone
Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)
Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)</description>
          </group>
          <group group_id="O3">
            <title>rhGH + Rosi Placebo</title>
            <description>Recombinant human growth hormone + placebo for rosiglitazone
Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)
Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)</description>
          </group>
          <group group_id="O4">
            <title>Double Placebo</title>
            <description>Placebo for recombinant human growth hormone + placebo for rosiglitazone
Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)
Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visceral Adipose Tissue Volume</title>
          <description>Change in visceral adipose tissue volume from baseline to week 12 measured by whole body MRI
Data are presented only for subjects who had MRI scans done at both time points.</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.13" spread="1.41"/>
                    <measurement group_id="O2" value="-0.19" spread="0.69"/>
                    <measurement group_id="O3" value="-1.15" spread="0.81"/>
                    <measurement group_id="O4" value="-0.04" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Subcutaneous Adipose Tissue Volume</title>
        <description>Change in subcutaneous adipose tissue volume from baseline to week 12 by whole body MRI
Data are presented only for subjects who had MRI scans done at both time points.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rhGH + Rosi</title>
            <description>Recombinant human growth hormone + rosiglitazone
Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)
Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)</description>
          </group>
          <group group_id="O2">
            <title>rhGH Placebo + Rosi</title>
            <description>Placebo for recombinant human growth hormone + rosiglitazone
Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)
Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)</description>
          </group>
          <group group_id="O3">
            <title>rhGH + Rosi Placebo</title>
            <description>Recombinant human growth hormone + placebo for rosiglitazone
Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)
Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)</description>
          </group>
          <group group_id="O4">
            <title>Double Placebo</title>
            <description>Placebo for recombinant human growth hormone + placebo for rosiglitazone
Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)
Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Subcutaneous Adipose Tissue Volume</title>
          <description>Change in subcutaneous adipose tissue volume from baseline to week 12 by whole body MRI
Data are presented only for subjects who had MRI scans done at both time points.</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="3.33"/>
                    <measurement group_id="O2" value="0.74" spread="1.86"/>
                    <measurement group_id="O3" value="-0.38" spread="1.23"/>
                    <measurement group_id="O4" value="-0.03" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The denominator for adverse events by treatment arm reflects the number of subjects who initiated study treatment in each arm. The denominator for serious adverse events reflects the number of randomized subjects since one serious adverse event occurred in someone who never initiated study drugs. Therefore the denominators differ.</desc>
      <group_list>
        <group group_id="E1">
          <title>rhGH + Rosi</title>
          <description>Recombinant human growth hormone + rosiglitazone
Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)
Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)</description>
        </group>
        <group group_id="E2">
          <title>rhGH Placebo + Rosi</title>
          <description>Placebo for recombinant human growth hormone + rosiglitazone
Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)
Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)</description>
        </group>
        <group group_id="E3">
          <title>rhGH + Rosi Placebo</title>
          <description>Recombinant human growth hormone + placebo for rosiglitazone
Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)
Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)</description>
        </group>
        <group group_id="E4">
          <title>Double Placebo</title>
          <description>Placebo for recombinant human growth hormone + placebo for rosiglitazone
Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)
Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever of undetermined origin</sub_title>
                <description>FUO was considered not related to study drugs. Ultimately found to be on doube placebo.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Study drug overdose</sub_title>
                <description>Patient injected rhGH or placebo twice daily instead of once daily but had no adverse effects. She was ultimately found to be on rhGH placebo.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <description>Patient with underlying seizure disorder who was nonadherent with anticonvulsant therapy and withdrawing from methadone. The delirium was attributed to a post-ictal state.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Leg weakness and pain</sub_title>
                <description>Patient with known myelopathy and multiple episodes of leg pain and weakness was admitted to the hospital with recurrent symptoms thought to be unrelated to study drugs. Ultimately found to be on double placebo.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Ureteral obstruction</sub_title>
                <description>Patient admitted to hospital with ureteral obstruction due to a kidney stone. Had known history of nephrolithiasis. Ultimately found to be on double placebo.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Cough/upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased ALT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Increased AST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Parethesias</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast enlargement/tenderness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Marshall J. Glesby</name_or_title>
      <organization>Weill Cornell Medical College</organization>
      <phone>212-746-4177</phone>
      <email>mag2005@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

